New Study Finds Survival Benefit Among Hospitalized Patients Undergoing Definity®- Enhanced Echocardiography

Lantheus Medical Imaging, Inc. a worldwide leader in diagnostic imaging, announced recently new data from a retrospective, multicenter, cohort study of over four million hospitalized patients that shows similar unadjusted mortality rates for patients receiving DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension enhanced resting echocardiography exams when compared with patients who did not receive DEFINITY®.

More: continued here

Filed under: MRI / PET / Ultrasound on January 4th, 2009